NASDAQ:ATRC

AtriCure - ATRC Stock Forecast, Price & News

$39.85

+0.31 (+0.78%)

(As of 09/30/2022 01:55 PM ET)

Add

Compare

Today's Range: $39.50
▼
$40.98
50-Day Range: $38.25
▼
$52.62
52-Week Range: $32.83
▼
$89.18

Volume: 5,587 shs
Average Volume: 257,214 shs
Market Capitalization: $1.85 billion

P/E Ratio: 34.35
Dividend Yield: N/A
Price Target: $75.86

AtriCure MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 90.4% Upside
$75.86 Price Target
Short Interest: Healthy
3.75% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.79
Based on 5 Articles This Week
Insider Trading: Selling Shares
$229,168 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.09) to ($0.90) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.54 out of 5 stars

Medical Sector

175th out of 1,097 stocks

Surgical & Medical Instruments Industry

18th out of 107 stocks

3.5

Analyst's Opinion

Consensus Rating
AtriCure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $75.86, AtriCure has a forecasted upside of 90.4% from its current price of $39.85.
Amount of Analyst Coverage
AtriCure has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
3.75% of the float of AtriCure has been sold short.
Short Interest Ratio / Days to Cover
AtriCure has a short interest ratio ("days to cover") of 6.6.
Change versus previous month
Short interest in AtriCure has recently decreased by 11.98%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
AtriCure does not currently pay a dividend.
Dividend Growth
AtriCure does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ATRC.

2.1

News and Social Media Coverage

News Sentiment
AtriCure has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for AtriCure this week, compared to 2 articles on an average week.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $229,168.00 in company stock.
Percentage Held by Insiders
Only 2.80% of the stock of AtriCure is held by insiders.
Percentage Held by Institutions
95.21% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for AtriCure are expected to grow in the coming year, from ($1.09) to ($0.90) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AtriCure is 34.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 118.37.
Price to Earnings Ratio vs. Sector
The P/E ratio of AtriCure is 34.35, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 90.40.
Price to Book Value per Share Ratio
AtriCure has a P/B Ratio of 3.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About AtriCure (NASDAQ:ATRC) Stock

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Receive ATRC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter.

ATRC Stock News Headlines

September 23, 2022 | nasdaq.com

Oversold Conditions For AtriCure (ATRC) - Nasdaq

September 22, 2022 | americanbankingnews.com

Insider Selling: AtriCure, Inc. (NASDAQ:ATRC) Insider Sells 4,983 Shares of Stock

September 13, 2022 | nasdaq.com

Notable Monday Option Activity: ATRC, TXN, RRX - Nasdaq

September 6, 2022 | businesswire.com

AtriCure Announces Investor Education Webcast with Hybrid AF Therapy Key Opinion Leaders - Business Wire

September 6, 2022 | finance.yahoo.com

AtriCure Announces Investor Education Webcast with Hybrid AF Therapy Key Opinion Leaders

August 30, 2022 | benzinga.com

Ablation Technology Market Size Worth US$ 18.09 billion to grow at a CAGR of 8.9% from 2022 to 2030| Gro - Benzinga

August 16, 2022 | benzinga.com

AtriCure to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference - Benzinga

August 16, 2022 | finance.yahoo.com

AtriCure to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference - Yahoo Finance

August 16, 2022 | finance.yahoo.com

AtriCure to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

August 7, 2022 | nasdaq.com

US$64.00: That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After Its Latest Results - Nasdaq

August 4, 2022 | benzinga.com

5 Analysts Have This to Say About AtriCure - Benzinga

August 3, 2022 | nasdaq.com

ATRC Sees 18-21% Revenue Growth, EVH Q2 Results Beat Estimates, EXAS Trims Outlook, HRMY On Watch... - Nasdaq

August 2, 2022 | investing.com

AtriCure Misses Q2 EPS by 3c By Investing.com - Investing.com

August 2, 2022 | uk.investing.com

AtriCure Misses Q2 EPS by 3c By Investing.com - Investing.com UK

August 2, 2022 | businesswire.com

AtriCure Reports Second Quarter 2022 Financial Results - Business Wire

August 2, 2022 | finance.yahoo.com

Is AtriCure (NASDAQ:ATRC) Using Too Much Debt?

July 23, 2022 | nasdaq.com

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way? - Nasdaq

July 18, 2022 | benzinga.com

5 Analysts Have This to Say About AtriCure - Benzinga - Benzinga

July 13, 2022 | finance.yahoo.com

Cardiac Ablation Market worth USD 11 Billion by 2030, says Global Market Insights Inc. - Yahoo Finance

July 12, 2022 | finance.yahoo.com

AtriCure to Announce Second Quarter 2022 Financial Results - Yahoo Finance

July 12, 2022 | finance.yahoo.com

AtriCure to Announce Second Quarter 2022 Financial Results

July 6, 2022 | finance.yahoo.com

Cardiac Arrhythmia Monitoring Devices Market to Grow by a Substantial CAGR of 6.33% by 2027, As per DelveInsight - Yahoo Finance

June 28, 2022 | benzinga.com

Analyst Ratings for AtriCure - Benzinga - Benzinga

June 27, 2022 | businesswire.com

Global Coronary Artery Bypass Graft Surgery Pipeline Report 2022 Update - ResearchAndMarkets.com - Business Wire

June 24, 2022 | benzinga.com

BTIG Maintains Buy on AtriCure, Lowers Price Target to $75 - Benzinga - Benzinga

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ATRC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter.

ATRC Company Calendar

Last Earnings: 8/02/2022
Today: 9/30/2022
Next Earnings (Estimated): 11/02/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: Health Care Equipment
Sector: Medical
Current Symbol: NASDAQ:ATRC
CUSIP: 04963C20
CIK: 1323885
Web: www.atricure.com
Phone: (513) 755-4100
Fax: 513-755-4567
Employees: 875
Year Founded: 2000

Price Target and Rating

Average Stock Price Forecast: $75.86
High Stock Price Forecast: $110.00
Low Stock Price Forecast: $50.00
Forecasted Upside/Downside: +90.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.16
Trailing P/E Ratio: 34.35
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $50.20 million
Net Margins: 17.62%
Pretax Margin: 17.68%
Return on Equity: -11.47%
Return on Assets: -9.04%

Debt

Debt-to-Equity Ratio: 0.15
Current Ratio: 3.66
Quick Ratio: 2.93

Sales & Book Value

Annual Sales: $274.33 million
Price / Sales: 6.74
Cash Flow: $0.96 per share
Price / Cash Flow: 41.57
Book Value: $10.53 per share
Price / Book: 3.78

Miscellaneous

Outstanding Shares: 46,420,000
Free Float: 45,125,000
Market Cap: $1.85 billion
Optionable: Optionable
Beta: 1.21

Social Links

Key Executives

Mr. Michael H. Carrel (Age 51)
CEO, Pres & Director
Comp: $1.94M

Ms. Angela L. Wirick CPA (Age 44)
Chief Financial Officer
Comp: $694.64k

Mr. Douglas J. Seith (Age 56)
Chief Operating Officer
Comp: $1.17M

Dr. Vinayak Doraiswamy Ph.D. (Age 50)
Chief Scientific Officer
Comp: $777.66k

Mr. Justin J. Noznesky (Age 44)
Chief Marketing & Strategy Officer
Comp: $700.74k

Mr. Salvatore Privitera J.D. (Age 55)
Chief Technical Officer

Mr. Karl S. Dahlquist C.C.E.P. (Age 52)
CCEP, J.D., Chief Legal & Compliance Officer

Valerie Storch-Willhaus
VP of Corp. Marketing & Communications

Ms. Tonya A. Austin SPHR (Age 50)
Sr. VP of HR

Ms. Deborah Yount
Chief HR Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ATRC Stock - Frequently Asked Questions

Should I buy or sell AtriCure stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ATRC shares.
View ATRC analyst ratings or view top-rated stocks.
What is AtriCure's stock price forecast for 2022?: 5 Wall Street analysts have issued 1-year price targets for AtriCure's shares. Their ATRC share price forecasts range from $50.00 to $110.00. On average, they anticipate the company's stock price to reach $75.86 in the next twelve months. This suggests a possible upside of 89.2% from the stock's current price.
View analysts price targets for ATRC or view top-rated stocks among Wall Street analysts.
How have ATRC shares performed in 2022?: AtriCure's stock was trading at $69.53 at the beginning of the year. Since then, ATRC stock has decreased by 42.3% and is now trading at $40.09.
View the best growth stocks for 2022 here.
When is AtriCure's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our ATRC earnings forecast.
How were AtriCure's earnings last quarter?: AtriCure, Inc. (NASDAQ:ATRC) posted its earnings results on Tuesday, August, 2nd. The medical device company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.30) by $0.02. AtriCure had a negative trailing twelve-month return on equity of 11.47% and a net margin of 17.62%. During the same quarter in the prior year, the company earned ($0.30) earnings per share.
What guidance has AtriCure issued on next quarter's earnings?: AtriCure updated its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided EPS guidance of -$1.12--$1.07 for the period, compared to the consensus EPS estimate of -$1.10. The company issued revenue guidance of $323.00 million-$333.00 million, compared to the consensus revenue estimate of $324.43 million.

What is Michael Carrel's approval rating as AtriCure's CEO?: 38 employees have rated AtriCure Chief Executive Officer Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among the company's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at AtriCure to a friend.
What other stocks do shareholders of AtriCure own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV), Gilead Sciences (GILD), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Enterprise Products Partners (EPD), Abbott Laboratories (ABT), Neurocrine Biosciences (NBIX), NVIDIA (NVDA), Pfizer (PFE) and Sarepta Therapeutics (SRPT).
What is AtriCure's stock symbol?: AtriCure trades on the NASDAQ under the ticker symbol "ATRC."
How do I buy shares of AtriCure?: Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is AtriCure's stock price today?: One share of ATRC stock can currently be purchased for approximately $40.09.
How much money does AtriCure make?: AtriCure (NASDAQ:ATRC) has a market capitalization of $1.86 billion and generates $274.33 million in revenue each year. The medical device company earns $50.20 million in net income (profit) each year or $1.16 on an earnings per share basis.
How many employees does AtriCure have?: The company employs 875 workers across the globe.
Does AtriCure have any subsidiaries?: The following companies are subsidiares of AtriCure: SentreHEART.
Read More
How can I contact AtriCure?: AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The official website for the company is www.atricure.com. The medical device company can be reached via phone at (513) 755-4100, via email at lynn@gilmartinir.com, or via fax at 513-755-4567.

This page (NASDAQ:ATRC) was last updated on 9/30/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

AtriCure - ATRC Stock Forecast, Price & News

AtriCure MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month